Chugai Pharma France - rezultati iskanja

Belgija - angleščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

granocyte 34 1 10*6 iu/ml inf. sol. (pwdr. + solv.) s.c./i.v. pre-filled syr. vial

chugai pharma france - lenograstim 263 - powder and solvent for solution for infusion - 1 miu/ml - lenograstim (rhug-csf) 263 µg - lenograstim

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

roactemra 162mg0.9ml solution for injection pre-filled syringes

roche products ltd - tocilizumab - solution for injection - 180mg/1ml

Evropska unija - angleščina - EMA (European Medicines Agency)

roactemra

roche registration gmbh - tocilizumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; cytokine release syndrome; giant cell arteritis; covid-19 virus infection - immunosuppressants - roactemra, in combination with methotrexate (mtx), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of giant cell arteritis (gca) in adult patients.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

akynzeo 300mg0.5mg capsules

chugai pharma uk ltd - palonosetron hydrochloride; netupitant - capsule - 500microgram ; 300mg